Tackling COVID-19 with neutralizing monoclonal antibodies
- PMID: 34416148
- PMCID: PMC8375150
- DOI: 10.1016/j.cell.2021.07.027
Tackling COVID-19 with neutralizing monoclonal antibodies
Figures




Erratum for
-
Tackling COVID-19 with neutralizing monoclonal antibodies.Cell. 2021 Jun 10;184(12):3086-3108. doi: 10.1016/j.cell.2021.05.005. Epub 2021 May 26. Cell. 2021. PMID: 34087172 Free PMC article. Review.
Similar articles
-
Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.Cell Rep. 2020 Jul 21;32(3):107918. doi: 10.1016/j.celrep.2020.107918. Epub 2020 Jul 3. Cell Rep. 2020. PMID: 32668215 Free PMC article.
-
Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.Front Med. 2021 Aug;15(4):644-648. doi: 10.1007/s11684-021-0847-4. Epub 2021 Apr 28. Front Med. 2021. PMID: 33909259 Free PMC article.
-
Tackling influenza with broadly neutralizing antibodies.Curr Opin Virol. 2017 Jun;24:60-69. doi: 10.1016/j.coviro.2017.03.002. Epub 2017 May 18. Curr Opin Virol. 2017. PMID: 28527859 Free PMC article. Review.
-
Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.J Virol Methods. 2021 Jan;287:113995. doi: 10.1016/j.jviromet.2020.113995. Epub 2020 Oct 14. J Virol Methods. 2021. PMID: 33068703 Free PMC article.
-
[Recombinant antibodies against bioweapons].Med Sci (Paris). 2009 Dec;25(12):1145-8. doi: 10.1051/medsci/200925121145. Med Sci (Paris). 2009. PMID: 20035695 Review. French.
Cited by
-
A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD.Signal Transduct Target Ther. 2022 Apr 5;7(1):114. doi: 10.1038/s41392-022-00954-8. Signal Transduct Target Ther. 2022. PMID: 35383141 Free PMC article.
-
Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines.Biomed Pharmacother. 2022 Feb;146:112527. doi: 10.1016/j.biopha.2021.112527. Epub 2021 Dec 10. Biomed Pharmacother. 2022. PMID: 34906769 Free PMC article. Review.
-
Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2.MAbs. 2023 Jan-Dec;15(1):2212415. doi: 10.1080/19420862.2023.2212415. MAbs. 2023. PMID: 37229608 Free PMC article.
-
Underuse of SARS-CoV-2-Neutralizing Monoclonal Antibodies in Skilled Nursing Facilities.J Am Med Dir Assoc. 2024 Feb;25(2):290-295. doi: 10.1016/j.jamda.2023.10.003. Epub 2023 Nov 6. J Am Med Dir Assoc. 2024. PMID: 37944905 Free PMC article.
-
Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant.Microbiol Spectr. 2022 Aug 31;10(4):e0270621. doi: 10.1128/spectrum.02706-21. Epub 2022 Jul 5. Microbiol Spectr. 2022. PMID: 35867411 Free PMC article. Clinical Trial.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources